SSY Group Limited (formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd.) is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group is principally engaged in the research, development, manufacture and sale of a wide range of pharmaceutical products mainly intravenous infusion solution.

The Group's production lines have combined the world's most advanced equipments and technologies, achieved full automation and information in production and logistics processes, and reached the international advanced level. The Group has distinct advantages in green production including low-cost, low-power consumption and zero-pollution.

The Group regards the product quality as our lives, and strictly follows the GMP requirements in organisation of production. It establishes and implements superior ideas and initiatives in services, and guarantees the health of many patients, both domestic and international, with excellent product quality and service.

The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005.